Capricor Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $6.39
- Today's High:
- $6.7
- Open Price:
- $6.39
- 52W Low:
- $3.3
- 52W High:
- $6.58
- Prev. Close:
- $6.49
- Volume:
- 109756
Company Statistics
- Market Cap.:
- $114.98 million
- Book Value:
- 0.246
- Revenue TTM:
- $5.54 million
- Operating Margin TTM:
- -542.61%
- Gross Profit TTM:
- $1.75 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -31.62%
- Return on Equity TTM:
- -187.82%
Company Profile
Capricor Therapeutics Inc had its IPO on 2007-02-13 under the ticker symbol CAPR.
The company operates in the Healthcare sector and Biotechnology industry. Capricor Therapeutics Inc has a staff strength of 74 employees.
Stock update
Shares of Capricor Therapeutics Inc opened at $6.39 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $6.39 - $6.7, and closed at $6.46.
This is a -0.46% slip from the previous day's closing price.
A total volume of 109,756 shares were traded at the close of the day’s session.
In the last one week, shares of Capricor Therapeutics Inc have slipped by -2.27%.
Capricor Therapeutics Inc's Key Ratios
Capricor Therapeutics Inc has a market cap of $114.98 million, indicating a price to book ratio of 6.4959 and a price to sales ratio of 61.6934.
In the last 12-months Capricor Therapeutics Inc’s revenue was $5.54 million with a gross profit of $1.75 million and an EBITDA of $-29379816. The EBITDA ratio measures Capricor Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Capricor Therapeutics Inc’s operating margin was -542.61% while its return on assets stood at -31.62% with a return of equity of -187.82%.
In Q1, Capricor Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 100%.
Capricor Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-1.18 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Capricor Therapeutics Inc’s profitability.
Capricor Therapeutics Inc stock is trading at a EV to sales ratio of 35.4213 and a EV to EBITDA ratio of -2.0433. Its price to sales ratio in the trailing 12-months stood at 61.6934.
Capricor Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $53.86 million
- Total Liabilities
- $37.13 million
- Operating Cash Flow
- $-3211695.00
- Capital Expenditure
- $453115
- Dividend Payout Ratio
- 0%
Capricor Therapeutics Inc ended 2024 with $53.86 million in total assets and $0 in total liabilities. Its intangible assets were valued at $53.86 million while shareholder equity stood at $6.21 million.
Capricor Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $37.13 million in other current liabilities, 25255.00 in common stock, $-144848077.00 in retained earnings and $0 in goodwill. Its cash balance stood at $10.61 million and cash and short-term investments were $45.17 million. The company’s total short-term debt was $693,652 while long-term debt stood at $3.38 million.
Capricor Therapeutics Inc’s total current assets stands at $46.59 million while long-term investments were $0 and short-term investments were $34.57 million. Its net receivables were $547580.00 compared to accounts payable of $5.43 million and inventory worth $0.
In 2024, Capricor Therapeutics Inc's operating cash flow was $-3211695.00 while its capital expenditure stood at $453115.
Comparatively, Capricor Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $6.46
- 52-Week High
- $6.58
- 52-Week Low
- $3.3
- Analyst Target Price
- $15
Capricor Therapeutics Inc stock is currently trading at $6.46 per share. It touched a 52-week high of $6.58 and a 52-week low of $6.58. Analysts tracking the stock have a 12-month average target price of $15.
Its 50-day moving average was $5.59 and 200-day moving average was $4.6 The short ratio stood at 5.18 indicating a short percent outstanding of 0%.
Around 274.1% of the company’s stock are held by insiders while 1090% are held by institutions.
Frequently Asked Questions About Capricor Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome platform technology which generated two vaccine candidates, such as STX-S and STX-N, induced an immune response against two SARS-CoV-2 proteins, spike, and nucleocapsid, as well as developing vaccines and therapeutics for infectious and monogenic diseases, and other potential indications. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.